Introduction {#sec1-1}
============

Hemoglobinopathies are inherited disorders characterized by anomalies of structure, function or production of globin chains that lead to a low or absent production of hemoglobin (Hb) with a consequent wide clinical and phenotypic heterogeneity.^[@ref1]^ Increased expression of fetal Hb (HbF) during adult life may ameliorate the clinical course of these disorders. In sickle cell disease (SCD), the beneficial effects of HbF are the inhibition of sickle Hb (HbS) polymerization, and dilution of the HbS concentration in the red blood cells while in β-thalassemia, yglobin chains can substitute for β-globin chains and prevent the excess of a-globin chains from damaging the red blood cells membrane.^[@ref1]^ Multiple pharmacological agents able to increase HbF production have been investigated and hydroxyurea (HU) is the only inducer approved for the treatment of adult patients affected by sickle cell disease^[@ref2]^ which entered into clinical practice for β-thalassemia intermedia (β-TI).^[@ref3]^ However, there is a great variability in the response of patients after HU therapy, in fact some patients are good responders while others exhibit little or no change in HbF levels.^[@ref4],[@ref5]^ Moreover, in responder patients, a decrease in the efficacy during long-term treatment was observed.^[@ref6],[@ref7]^

Liquid erythroid cultures, a system reproducing erythropoiesis *in vitro*, are a useful model to study human erythroid cells. It was previously shown that the γ-globin mRNA fold increase in cultured erythroid progenitors exposed to HU, correlates to the *in vivo* HbF fold increase observed in patients after HU therapy.^[@ref6]^ This approach is used as an *in vitro* test, the only current method able to predict *in vivo* patients response to the drug.

Several genetic factors can influence the severity of haemoglobinopathies; some of them act by reducing the degree of a/β imbalance (co-inheritance of a-thalassemia) while others act by increasing HbF levels.

There is a broad range of basal HbF levels among individuals; single nucleotide polymorphisms (SNPs) or deletions within the beta globin cluster account for a portion of this variation. Moreover genetic studies are being done to detect the determinants influencing HbF levels by trans-acting factors not linked to the β-globin cluster. Genome-wide association studies (GWAS) have identified quantitative trait *loci* (QTLs) that affect baseline HbF levels in patients with Hb disorders. Several SNPs in these *loci* seem to be responsible for an estimated 15 to 20% of individual variation in HbF levels.^[@ref8]^ A well-known HbF QTL is the XmnI polymorphism (rs7482144), a C T substitution at position -158 of the Gγ globin gene promoter.^[@ref9]^ Early reports and GWAS studies show that the presence of the XmnI T allele correlates with higher HbF levels in β-thalassemia and SCD patients.^[@ref10]^

Another HbF QTL is the *BCL11A* gene, that codify for a γ-globin gene repressor.^[@ref13]^ Several GWAS studies have associated SNPs in intron 2 of the *BCL11A* gene *(e.g.* rs11886868 and rs4671393) with higher HbF levels in patients with hemoglobinopathies.^[@ref12],[@ref14]^ In particular, a strong association between rs11886868 and HbF level was highlighted in the Sardinian population.^[@ref15]^ High HbF levels have been also associated with rs4671393 SNP (A/A genotype) in two different SCD cohorts (African American Cooperative Study of Sickle Cell Disease and SCD cohort from Brazil).^[@ref12]^

Biological variability in HbF levels is also influenced by genes involved in y-globin gene expression such as *KLF-1* and *GATA-1.* Certain mutations within the *KLF-1* transcription factor gene result in persistent high-level of HbF (HPFH) after birth.^[@ref16]^ In a Maltese family a single mutation located in *KLF-1* exon 2 (K288X) causing HPFH was shown to produce the lack of a DNA binding domain.^[@ref17]^

Moreover the identification of a mutation in *GATA-1* gene (R216W) in a child affected by congenital erythropoietic porphyria and β-thalassemia showing increased HbF level, suggests also an important role for *GATA-1* in globin chain switching.^[@ref18]^

The identification of pharmacogenomic biomarkers is important to predict pharmacological treatment efficacy. To date few studies have been conducted to evaluate the role of the genetic determinants in HU response.

Some studies have shown an association between the XmnI T/T and *BCL11A* rs 766432 markers and response to HU.^[@ref14],[@ref19],[@ref20]^ Conversely, other studies have failed to detect the correlation between XmnI genotype and HU response.^[@ref21]^

The aim of this study was to analyze *BCL11A, GATA-1, KLF-1* genes and γ-globin promoter in 60 alleles from 30 hemoglobinopathies patients to assess if there is a significant association between these genetic determinants and the efficacy of HU treatment. Furthermore in the same patients the response to HU was evaluated *in vitro* in a liquid erythroid culture system.

Materials and Methods {#sec1-2}
=====================

Cohort description {#sec2-1}
------------------

Thirty patients (12 males and 18 females) affected by SCD and thalassemia (1 βS/βS patient, 14 βS/β-thalassemia patients and 15 β-TI patients) were studied. Molecular studies for genotype detection were performed according to procedures reported elsewhere.^[@ref24]^ The patients characteristics are shown in [Table 1](#table001){ref-type="table"}. All the patients were treated with hydroxyurea. The mean dosage of HU administered was 16.4 mg/kg (range 9.2-21), and the mean follow-up time was 111 months (range 5-180).

Genotyping {#sec2-2}
----------

Peripheral blood in ethylene diamine tetraacetic acid-containing (EDTA) collection tubes was used to extract genomic DNA (standard phenol-cloroform method). DNA was amplified using the polymerase chain reaction (PCR): PCR mix (50 μL) contained 200 ng of genomic DNA, 1.5 μL of 10 pmol primers, 5 μL of buffer 10x, 1.5 μL of MgCI~2~ 50 mmol, 1 μL of 40 mmol dNTP and 2.5 U of Taq polymerase enzyme (Invitrogen Corp., Carlsbad, CA, USA). PCR products were analyzed on SYBR-Safe 3% agarose gel and displayed to the ultraviolet lamp. PCR products were sequenced bidirectional directly using Big-Dye terminator 3.1 cycle sequencing kit and run on ABI PRISM 3130 DNA analyzer (Applied Biosystems, Foster City, CA). Primers used for PCR and sequencing were designed in our laboratory ([Table 2](#table002){ref-type="table"}). Mutations in *KLF-1* were detected by DNA sequencing of exon 2; mutations of *BCL11A* were found by sequencing of the 5 exons and the two intronic regions containing SNP rs11886868 and rs4671393. For the analysis of *GATA1* gene the entire codifying region (6 exons) was sequenced. Also the XmnI genotype was obtained by XmnI enzymatic restriction. The PCR conditions will be made available upon request.

Two phase liquid primary erythroid cultures {#sec2-3}
-------------------------------------------

After informed consent was obtained, 20 mL of peripheral blood was withdrawn from 30 patients before HU treatment. Primary cell cultures were performed as previously described.^[@ref25]^ Mononuclear cells from peripheral blood were isolated by centrifugation over Ficoll-Hypaque (1.077 g/mL; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) at 1200 × g for 15 min. The nucleated cells were first cultured in a minimal essential medium (MEM) supplemented with 1 μg/mL cyclosporine A (Novartis Basilea, Switzerland), 10% fetal calf serum (FCS, Invitrogen, Carlsbad, California, USA) and 10% conditioned medium collected from cultures of the human bladder carcinoma 5637 cell line. After 6 days of incubation in phase I culture, the non-adherent cells were harvested, washed, and resuspended in phase II medium composed of α-MEM, 30% FCS, 1% deionized bovine serum albumin (Sigma-Aldrich, St. Louis, Missouri, USA), 10 mM 2- mercapto-ethanol (Sigma), 1.5 mM glutamine (Euroclone), 1 mM dexamethasone (Laboratorio Farmacologico Milanese, MI, Italy), 1U/mL recombinant erythropoietin (Janssen-Cilag, Leiden, The Netherlands), 10 ng/mL Stem Cell Factor (Sigma), and 0.3 mg/mL human holo-transferrin (Sigma). Cells were harvested at day 10 of phase II culture. We performed at least two different primary cultures for each patient.

Hydroxyurea treatment *in vitro* {#sec2-4}
--------------------------------

At day 6 of phase II, cells were washed with α-MEM, and the cell culture was split. Half of the culture was exposed to 100 μM HU (Teofarma Srl, Pavia, Italy), a dose that corresponds to the serum HU concentration during *in vivo* treatment at 20 mg/kg/day.^[@ref26]^ As a control, the other half of the culture was grown without the drug. At day 10, the cells were harvested and analyzed. At the 100 μM HU dosage, erythroid progenitors express the maximum potential of γ-mRNA expression, in that, when lower concentrations were tested (75 μM), the same γ-mRNA increase was obtained. Higher doses cause the cell death.

Flow cytometric analysis {#sec2-5}
------------------------

The phase II cultured cells were monitored for erythroid differentiation by measuring cellular expression of transferrin receptor (CD71- PE) (Immunotech, Marseille Cedex 9, France) and glycophorin A antigen (GPA-FITC) (Immunotech) as previously described.^[@ref27]^ Cells were analyzed using the Cytomics FC 500 (Beckman Coulter Inc., Fullerton, CA 92835).

Real-time quantitative polymerase chain reaction {#sec2-6}
------------------------------------------------

RNA was isolated with TRIzol® reagent (Invitrogen, Carlsbad CA 92008, USA) according to manufacturer's instructions. cDNA synthesis was carried out using High Capacity cDNA Reverse Transcription kit (Applied Biosystems) from 1 μg of total RNA. Quantitative real-time PCR assay of transcripts was then performed with the use of gene-specific double fluorescently-labeled probes in a 7900 Sequence Detector (Applied Biosystems, Norwalk, CT). All samples were assayed using TaqMan Universal PCR Master Mix (Applied Biosystems Foster City, CA, USA). The following primer and probe sequences were used: γ-globin forward primer, 5'- GGCAACCTGTCCTCTGCCTC-3'; γ-globin reverse primer, 5'-GAAATGGATTGCCAAAACGG-3'; γ-globin probe, 5'-FAMCAAGCTCCTGGGAAATGTGCTGGTG-TAMRA- 3'.^[@ref27]^ As endogenous control the human glyceraldehyde-3-phosphate dehydrogenase gene *(GAPDH)* (Pre-Developed Taqman assay control kit, Applied Biosystem) was used. The comparative threshold cycle (Ct) method was used to determine the difference (Ct) between the Ct of treated samples and the Ct of the untreated samples. Before subtraction, the Ct was normalized by the Ct of the endogenous reference gene, *GAPDH.* The experiments were performed in triplicate to ensure the reproducibility of results.

Statistical analysis {#sec2-7}
--------------------

Data are presented as mean±SD. χ square test was used to assess if there is statistical significance of the differences in the frequency of genetic variants among the hemoglobinopathies groups analyzed. R software and Microsoft Excel were used for the statistical analysis.

Results {#sec1-3}
=======

Primary erythroid cultures from peripheral blood hematopoietic stem cells of 30 patients (15 SCD and 15 β-TI) were performed. Flow cytometric analysis of erythroid markers (CD71 and GPA) did not show any difference during erythroid differentiation between cultures derived from HU responder and non-responder patients. For each sample, the effect of HU in terms of γ-globin mRNA fold increase respect to untreated cells was measured by mRNA relative quantification using a fluorescence-based quantitative real-time PCR assay. At least two different primary cultures for each sample were performed. The results of this analysis, predictive of patients' response to HU treatment, have been summarized in [Table 1](#table001){ref-type="table"}. After the *in vitro* study, all the patients started HU treatment *in vivo.* Nine β-TI patients attained an increase of their transfusion interval while 6 of them stopped the treatment since they did not show an increase in Hb or an appreciable change in blood transfusion intervals. In SCD patients HU treatment determined increase in HbF and total Hb and decrease in white blood cell counts. Moreover a reduction of vaso-occlusive crisis, acute chest syndromes and the other complications of the disease were observed. Only 1 SCD patient did not respond and stopped the treatment. After one to two years of treatment, when the *in vivo* response was stabilized, HbF fold increase was calculated and compared to γ-globin mRNA fold increase measured *in vitro.* For all patients a very good correlation between the *in vivo* and the *in vitro* HU response was observed (Pearson correlation = 0.95, P = 0.05). In fact, in all patients studied, the *in vitro* γ-globin mRNA fold increase was very similar to the *in vivo* HbF fold increase confirming the predictive value of the *in vitro* test. All the patients were studied for the presence of some genetic determinants responsible of high level of fetal hemoglobin production *(BCL11A*, -158 γ-globin gene promoter, *GATA-1* and *KLF-1).* Genotyping results are summarized in [Table 1](#table001){ref-type="table"}. No association between these genetic markers and HU response was found. Moreover, in exon 2 of *BCL11A* gene of 1 patient (n. 14) a new mutation (L45R/N) not previously described was detected. This mutation does not appear to be associated to HU response since the patient's brother (n. 13) that presents the same thalassemia genotype (β039/öβ), the same basal HbF level and the same response to HU treatment does not show the mutation.

A not previously described T insertion located 74 bp downstream to rs11886868 SNP of *BCL11A* gene was identified always associated to the T allele.

The XmnI polymorphism was found in heterozygous only in two responder patients (n. 3 and n. 18) while R216W mutation in the exon 4 of *GATA-1* gene and K288X in *KLF-1* gene were not found in any patient. A point mutation in exon 2 of *KLF-1* gene causing the aminoacid substitution F182L (c.544T\>C) was found in heterozygous in 3 patients.

Discussion and Conclusions {#sec1-4}
==========================

Hemoglobinopathies, such as SCD and thalassemia are among the most common human genetic disorders. HbF increase is of enormous clinical relevance given its role in ameliorating the severity of these diseases. Among the pharmacological agents able to induce HbF production, HU is the drug of choice for the treatment of hemoglobinopathies but patients' response to this drug varies considerably. For this reason the ability to predict HbF response to HU treatment would be helpful for the selection of responders to prevent potential adverse drug reactions in non-responder patients.

The regulation of HbF level is complex and involves elements and factors cis- and transacting to the β-globin cluster such as -158 Gγ globin gene promoter, *KLF-1, BCL11A, GATA-1* and probably other regulatory *loci*; epigenetic and cellular factors could also have regulatory roles.^[@ref28]^ It is possible that these and also other genetic determinants modulate HbF response. The correlation of genetic determinants with high HbF levels after HU treatment was studied yielding contradictory results. In fact, although the presence of Xmn I polymorphism is more often associated with better response to HU therapy,^[@ref19],[@ref20]^ other studies did not find any association of such polymorphism with high HbF levels upon HU treatment.^[@ref22]^ In the present study, we examine the possible association of some HbF QTLs with the response to HU in 30 hemoglobinopathies patients. No association between these genetic markers and HU response is established, even if could be useful to extend this analysis to a larger cohort of patients to confirm these results. The response to HU therapy is complex and polymorphisms in many genes modulating γ-globin gene expression, HU metabolism and erythroid progenitor proliferation might affect patients' response. Statistically significant associations of HbF response to HU with multiple SNPs in several genes *(ARG2, FLT1, HAO2, NOS1, KLF10, SALL2)* have been reported.^[@ref29],[@ref30]^ To date the use of genetic determinants to predict the effect of HU is still not possible. For this reason human liquid erythroid culture system, an efficacious but complex and time consuming approach, at the moment remains the only method able to predict patients' response to HU.

Nevertheless recent advances in genomic analysis technologies, including next generation sequencing and microarrays will provide revolutionary opportunities allowing to analyze a large number of genes and patients simultaneously for the search of genetic determinants that could help to trace a genetic profile rather than single mutations that may be predictive of pharmacological response.

###### 

Genotyping results and correlation between *in vitro* and *in vivo* response.

  ID   Gender   Genotype          BCL11A rs4671393 rs11886868   BCL11A     KLF-1    -158      GATA-1   γ-globin mRNA increase   *In vivo* response   
  ---- -------- ----------------- ----------------------------- ---------- -------- --------- -------- ------------------------ -------------------- --------------------------
  1    M        IVSI, 110/-87     G/G                           T/T +ins   w.t.     F182L/N   C/C      w.t.                     1.3±0.2              YES (1.24 fold increase)
  2    F        IVS I,1/-101      A/G                           C/C        w.t.     w.t.      C/C      w.t.                     1.2±0.2              NO (1.29 fold increase)
  3    F        IVS I,6/IVS I,6   G/G                           T/T +ins   w.t.     w.t.      T/C      w.t.                     1.5±0.1              YES (1.31 fold increase)
  4    M        IVS I,6/IVS I,6   A/A                           C/C        w.t.     w.t.      C/C      w.t.                     1.5±0.2              NO (1.69 fold increase)
  5    M        IVS I,6/IVS I,6   A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     3±0.1                NO (2.68 fold increase)
  6    F        IVS I,6/IVS I,6   A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     2±0                  NO (2.3 fold increase)
  7    M        IVS I,6/IVS I,6   A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     2±0                  NO (2.15 fold increase)
  8    F        β039/IVS I, 6     G/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.8±0.1              YES (1.59 fold increase)
  9    F        β039/IVS I, 6     A/A                           C/C        w.t.     w.t.      C/C      w.t.                     1±0.2                NO (1.10 fold increase)
  10   M        β039/IVS I, 6     A/A                           C/C        w.t.     w.t.      C/C      w.t.                     1±0.2                YES (1.20 fold increase)
  11   M        β039/IVS I, 6     A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.8±0.2              YES (1.57 fold increase)
  12   M        βLepore/βLepore   G/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.8±0.3              YES (1.58 fold increase)
  13   M        öβ/β039           A/A                           C/C        w.t.     w.t.      C/C      w.t.                     1.4±0.2              YES (1,15 fold increase)
  14   F        öβ/β039           A/G                           C/T +ins   L45R/N   w.t.      C/C      w.t.                     1.3±0.2              YES (1.29 fold increase)
  15   F        cod6/β039         A/G                           C/T +ins   w.t.     F182L/N   C/C      w.t.                     1±0                  YES (1.17 fold increase)
  16   M        βS/β039           G/G                           T/T +ins   w.t.     w.t.      C/C      w.t.                     1.3±0.2              YES (1.5 fold increase)
  17   F        βS/β039           A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     2.7±0.3              YES (3 fold increase)
  18   M        βS/β039           G/G                           T/T +ins   w.t.     w.t.      T/C      w.t.                     1.2±0.2              YES (1.06 fold increase)
  19   F        βS/β039           A/G                           C/C        w.t.     F182L/N   C/C      w.t.                     1.7±0.2              YES (1.85 fold increase)
  20   F        βS/β039           A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.4±0.1              YES (1.51 fold increase)
  21   F        βS/β039           G/G                           T/T +ins   w.t.     w.t.      C/C      w.t.                     2.2±0.3              YES (1.87 fold increase)
  22   F        βS/β039           G/G                           T/T +ins   w.t.     w.t.      C/C      w.t.                     3±0                  YES (3.04 fold increase)
  23   M        βS/IVSI, 110      A/G                           C/C        w.t.     w.t.      C/C      w.t.                     2.5±0.2              YES (2.56 fold increase)
  24   F        βS/IVSI, 110      A/A                           C/C        w.t.     w.t.      C/C      w.t.                     2.3±0.2              YES (2.83 fold increase)
  25   F        βS/IVSI, 110      A/A                           C/C        w.t.     w.t.      C/C      w.t.                     1±0                  YES (1,11 fold increase)
  26   F        βS/IVSI, 110      G/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.6±0.2              YES (1.81 fold increae)
  27   F        βs/IVS II, 745    A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1.7±0.2              NO (1.79 fold increase)
  28   M        βS/öβ             A/G                           C/T +ins   w.t.     w.t.      C/C      w.t.                     1±0                  YES (1.22 fold increase)
  29   M        βS/βS             G/G                           T/T +ins   w.t.     w.t.      C/C      w.t.                     1.2 ±0.1             YES (1.24 fold increase)
  30   F        βs/IVS I, 5c      G/G                           T/T +ins   w.t.     w.t.      C/C      w.t.                     1.3±0.2              YES (1.35 fold increase)

###### 

Primer used for amplification and detection of the single nucleotide polymorphisms and alleles.

  Allele          Transcription           Primers sequence (5'\<3')
  --------------- ----------------------- -----------------------------
  rs 4671393      Forward                 CACTAGCTCAGAAATGGACTT
  Reverse         ACCTTCCTTTAATCAGCTTCC   
  rs 11886868     Forward                 ATCAGATACAGAACACGTCC
  Reverse         GTCCATTGTAGCACTGTTCAT   
  KLF-1 exon 2b   Forward                 AGACTCTGGGCGCATATGCT
  Reverse         AGGAGGCACTCACTCTCAGA    
  BCL11A exon 1   Forward                 GGA TGT CAA AAG GCA CTG ATG
  Reverse         TCTCTTTTACCTCGACTCTCG   
  BCL11A exon 2   Forward                 TTACATGATGTGGTGGGATGG
  Reverse         GCTGTCATGGACAGTCACATA   
  BCL11A exon 3   Forward                 CTGGGAAATAACTCACCACTC
  Reverse         GCTGCCAAGTGAGTAATGGAA   
  BCL11A exon 4   Forward                 GGCTGGAGGTGGAACATAAAT
  Reverse         TCTCTCGATACTGATCCTGGT   
  BCL11A exon 5   Forward                 TCATGCTTAAGATGCCAGTGG
  Reverse         AAATAAAATGGCGCTGCAGGC   
  GATA-1 exon 1   Forward                 CAAGAGGTGCCCCACAAGCAT
  Reverse         GACACTTTGGGGACCAGCTGT   
  GATA-1 exon 2   Forward                 AGAAATATGGAGACTGAGGTG
  Reverse         ATCCTCACAGTGGTATTCTGA   
  GATA-1 exon 3   Forward                 TGTGGAGCTGGGAACTTG
  Reverse         TCAGCTCAGCTTTACTTTGGG   
  GATA-1 exon 4   Forward                 CCCTGTGGTGAGAAATTCAAA
  Reverse         GCAGTAGCTTCCTGTAATCAT   
  GATA-1 exon 5   Forward                 TTCAACCTGACCCTCACTTCT
  Reverse         GAGGTAGAACAGGAACAGAGT   
  GATA-1 exon 6   Forward                 TGAAAGAAGTGGGGTAGAGAG
  Reverse         AGAGAGCCACAGGCATTGTTA   
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